博森坦不影响硬化症/全身性硬化症患者的抗指数
Emma Di Poi1, GianLuca Colussi2, Martina Bertoni1
1Department of Medicine, University of Udine, Udine, Italy.
Kidney & blood pressure research
|November 8, 2023
概括
博森坦在患有数字的全身性硬化症患者中没有改善内血动力学. 治疗降低了血压和降低了功能 (eGFR).
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 系统性硬化症 (SSc) 患者患慢性病的患病率很高.
- 抗性指数 (RRI) 表示内血管抵抗,并预测SSc相关的血管病变.
- 博森坦是一种非选择性的内甲素-1受体对抗剂.
研究的目的:
- 为了评估博森坦对RRI和功能在SSc患者与数字的影响.
- 为了评估血压和尿路内甲蛋白-1水平的变化.
主要方法:
- 一项为期16周的前性,开放式,不受控制的研究.
- 招募了21名患有数字的SSc患者.
- 测量包括RRI (多普勒超声波),血压 (MAP,PP,D/S比率) 和估计的膜过率 (eGFR).
主要成果:
- 博森坦治疗没有改变RRI (p=0.925).
- 观察到尿内甲素-1与肌素比率显著增加 (p=0.032).
- 博森坦降低了平均动脉压 (MAP),脉冲压 (PP),D/S比率和eGFR (p<0.001对于MAP,p=0.003对于PP,p=0.006对于D/S,p=0.003对于eGFR).
结论:
- 博森坦在SSc患有数字的患者中没有对内血动力学产生影响.
- 这种药物导致了血压的降低.
- 博森坦与功能 (eGFR) 的下降有关.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
172
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
172
01:30Heart Failure V: Medical Management
9
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
9
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
163
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
163
01:22Heart Failure Drugs: β-Blockers
346
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346
01:25Antihypertensive Drugs: Direct Renin Inhibitors
648
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
648